Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term randomized withdrawal extension study of subcutaneous secukinumab in moderate to severe hidradenitis suppurativa
2023-508956-20-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Continued secukinumab with Withdrawal to placebo (2 arms). Primary endpoint: Time to loss of HiSCR response up to Week 104. Started Aug 2024; status: completed.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2023-508956-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508956-20-00.